Pseudoephedrine

A clinical trial with 34 participants investigated pseudoephedrine's effects on nasal congestion and sleep fragmentation in individuals with perennial allergic rhinitis, comparing FDA-approved doses to placebo.

A comprehensive review of pseudoephedrine's pharmacokinetics, benefits, and risks in healthy populations, documenting onset of action within 30 minutes, peak concentration at 1-4 hours, and duration of 4-12 hours.

A review of pseudoephedrine's efficacy as a nasal decongestant, noting that 60 mg is the optimal single adult dose achieving maximal nasal decongestion with minimal cardiovascular effects, while higher doses (120-180 mg) produce statistically significant increases in pulse and systolic blood pressure.

Seven male athletes completed 1500-meter running trials after receiving 2.5 mg/kg pseudoephedrine or placebo. Pseudoephedrine significantly decreased completion time by 2.1% with no reported side effects and no changes in measured blood parameters, suggesting a central effect.

A cycling time trial study comparing pseudoephedrine to placebo found a 5.1% improvement in performance with pseudoephedrine, with authors concluding that higher doses were responsible for the improvement.

Seven male athletes completed 1500-meter running trials after receiving 2.5 mg/kg pseudoephedrine or placebo. Pseudoephedrine significantly decreased completion time by 2.1% with no reported side effects and no changes in measured blood parameters, suggesting a central effect.

A cycling time trial study comparing pseudoephedrine to placebo found a 5.1% improvement in performance with pseudoephedrine, with authors concluding that higher doses were responsible for the improvement.

A review of pseudoephedrine's efficacy as a nasal decongestant, noting that 60 mg is the optimal single adult dose achieving maximal nasal decongestion with minimal cardiovascular effects, while higher doses (120-180 mg) produce statistically significant increases in pulse and systolic blood pressure.

A review of pseudoephedrine's efficacy as a nasal decongestant, noting that 60 mg is the optimal single adult dose achieving maximal nasal decongestion with minimal cardiovascular effects, while higher doses (120-180 mg) produce statistically significant increases in pulse and systolic blood pressure.

A review of pseudoephedrine's efficacy as a nasal decongestant, noting that 60 mg is the optimal single adult dose achieving maximal nasal decongestion with minimal cardiovascular effects, while higher doses (120-180 mg) produce statistically significant increases in pulse and systolic blood pressure.

Fifteen female track runners completed 800-meter time trials after receiving either 2.5 mg/kg pseudoephedrine or placebo in a crossover design. Results showed no significant difference in running times between conditions, with both averaging 2:39.4.